Search

Your search keyword '"Jukic, Lucija"' showing total 19 results
Start Over Author "Jukic, Lucija" Search Limiters Full Text
19 results on '"Jukic, Lucija"'

4. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy

Author

Mikolasevic, Ivana, primary, Domislovic, Viktor, additional, Krznaric-Zrnic, Irena, additional, Krznaric, Zeljko, additional, Virovic-Jukic, Lucija, additional, Stojsavljevic, Sanja, additional, Grgurevic, Ivica, additional, Milic, Sandra, additional, Vukoja, Ivan, additional, Puz, Petra, additional, Aralica, Merica, additional, and Hauser, Goran, additional

Published
2022
Full Text
View/download PDF

7. FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19

Author

Zelenika, Marko, primary, Lucijanic, Marko, additional, Bokun, Tomislav, additional, Bozin, Tonci, additional, Barisic Jaman, Mislav, additional, Tjesic Drinkovic, Ida, additional, Pastrovic, Frane, additional, Madir, Anita, additional, Luksic, Ivica, additional, Piskac Zivkovic, Nevenka, additional, Luetic, Kresimir, additional, Krznaric, Zeljko, additional, Ostojic, Rajko, additional, Filipec Kanizaj, Tajana, additional, Bogadi, Ivan, additional, Virovic Jukic, Lucija, additional, Kukla, Michal, additional, and Grgurevic, Ivica, additional

Published
2021
Full Text
View/download PDF

8. Prevalence and Prognostic Impact of Deranged Liver Blood Tests in COVID-19: Experience from the Regional COVID-19 Center over the Cohort of 3812 Hospitalized Patients

Author

Paštrovic, Frane, primary, Lucijanic, Marko, additional, Atic, Armin, additional, Stojic, Josip, additional, Barisic Jaman, Mislav, additional, Tjesic Drinkovic, Ida, additional, Zelenika, Marko, additional, Milosevic, Marko, additional, Medic, Barbara, additional, Loncar, Jelena, additional, Mijic, Maja, additional, Filipec Kanizaj, Tajana, additional, Kralj, Dominik, additional, Lerotic, Ivan, additional, Virovic Jukic, Lucija, additional, Ljubicic, Neven, additional, Luetic, Kresimir, additional, Grgic, Dora, additional, Majerovic, Matea, additional, Ostojic, Rajko, additional, Krznaric, Zeljko, additional, Luksic, Ivica, additional, Piskac Zivkovic, Nevenka, additional, Keres, Tatjana, additional, Grabovac, Vlatko, additional, Persec, Jasminka, additional, Barsic, Bruno, additional, and Grgurevic, Ivica, additional

Published
2021
Full Text
View/download PDF

16. Oil and Gas Futures and Options Market.

Author

Nosić, Ante, Sedlar, Daria Karasalihovic, and Jukic, Lucija

Subjects
ENERGY minerals, ENERGY industries, ENERGY consumption, LIQUEFIED natural gas, MARKETING strategy
Abstract

Copyright of Rudarsko-Geolosko-Naftni Zbornik is the property of Faculty of Mining, Geology & Petroleum Engineering and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017
Full Text
View/download PDF

18. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis.

Author

Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, and Smircic Duvnjak L

Abstract

Patients with nonalcoholic steatohepatitis (NASH) are at higher risk of progression to advanced stages of fibrosis, cirrhosis, hepatocellular carcinoma and other end-stage liver disease complications. When addressing treatment of NASH, we have limited approved options, and the mainstay of therapy is lifestyle intervention. Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials. These drugs target almost all steps in the pathogenesis of NASH to improve insulin sensitivity, glucose and lipid metabolism, to inhibit de novo lipogenesis and delivery of lipids to the liver, and to influence apoptosis, inflammation and fibrogenesis. Although NASH is a multifactorial disease, in the future we could identify the predominating pathological mechanism and, by choosing the most appropriate specific medication, tailor the treatment for every patient individually., Competing Interests: The authors have no conflict of interests related to this publication., (© 2021 Authors.)

Published
2021
Full Text
View/download PDF

19. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management.

Author

Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, and Mrzljak A

Subjects
Diabetes Mellitus, Type 2 etiology, Diabetes Mellitus, Type 2 metabolism, End Stage Liver Disease etiology, End Stage Liver Disease metabolism, Graft Rejection immunology, Graft Rejection prevention & control, Humans, Immunosuppressive Agents adverse effects, Liver Cirrhosis complications, Liver Cirrhosis metabolism, Liver Cirrhosis surgery, Metabolic Syndrome metabolism, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease surgery, Oxidative Stress drug effects, Postoperative Complications etiology, Postoperative Complications metabolism, Risk Factors, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Treatment Outcome, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2 drug therapy, End Stage Liver Disease surgery, Liver Transplantation adverse effects, Metabolic Syndrome complications, Postoperative Complications drug therapy, Sodium-Glucose Transporter 2 Inhibitors therapeutic use
Abstract

Liver cirrhosis and diabetes mellitus (DM) are both common conditions with significant socioeconomic burden and impact on morbidity and mortality. A bidirectional relationship exists between DM and liver cirrhosis regarding both etiology and disease-related complications. Type 2 DM (T2DM) is a well-recognized risk factor for chronic liver disease and vice-versa, DM may develop as a complication of cirrhosis, irrespective of its etiology. Liver transplantation (LT) represents an important treatment option for patients with end-stage liver disease due to non-alcoholic fatty liver disease (NAFLD), which represents a hepatic manifestation of metabolic syndrome and a common complication of T2DM. The metabolic risk factors including immunosuppressive drugs, can contribute to persistent or de novo development of DM and NAFLD after LT. T2DM, obesity, cardiovascular morbidities and renal impairment, frequently associated with metabolic syndrome and NAFLD, may have negative impact on short and long-term outcomes following LT. The treatment of DM in the context of chronic liver disease and post-transplant is challenging, but new emerging therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) targeting multiple mechanisms in the shared pathophysiology of disorders such as oxidative stress and chronic inflammation are a promising tool in future patient management., Competing Interests: Conflict-of-interest statement: No potential conflicts of interest., (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results